AMAG Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- AMAG Pharmaceuticals's total funding is $264.9M.
Employee Data
- AMAG Pharmaceuticals has 407 Employees.
- AMAG Pharmaceuticals grew their employee count by -1% last year.
AMAG Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is AMAG Pharmaceuticals?
Advanced Magnetics, Inc. is dedicated to the development and commercialization of therapeutic iron compounds for treating anemia as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol , the lead product in our development pipeline, has completed Phase II clinical studies for use as an iron replacement therapeutic in chronic kidney disease patients receiving erythropoietin. Ferumoxytol is also in Phase II clinical studies for use in magnetic resonance angiography, also known as MRA. In June 2000, we received an approvable letter, subject to certain conditions, from the U.S. Food and Drug Administration, the FDA, for Combidex®, our MRI contrast agent to aid in the diagnosis of lymph node disease. We are currently discussing the outstanding issues from the approvable letter with the FDA in an effort to bring Combidex to market. Our liver contrast agent, Feridex I.V.®, is approved and marketed in Europe, Japan, the United States, Argentina, South Korea and Israel. Our oral contrast agent, GastroMARK®, used for delineating the bowel in MRI procedures, is approved and marketed in Europe and the United States.
keywords:N/A$264.9M
Total Funding
407
Number of Employees
N/A
Revenue (est)
-1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AMAG Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Specialty Hematology Oncology Consultant | Reveal Email/Phone |
2 | SAR Hematology/Oncology - Oncology Field Trainer | Reveal Email/Phone |
3 | Sales Operations Analyst | Reveal Email/Phone |
4 | Executive SAR | Reveal Email/Phone |
5 | Senior Specialty Account Representative | Reveal Email/Phone |
6 | Director Government Programs and Price Reporting | Reveal Email/Phone |
7 | Senior Manager Patient Services | Reveal Email/Phone |
8 | Product Manager | Reveal Email/Phone |
9 | VP, Deputy General Counsel, Corporate | Reveal Email/Phone |
10 | Sr. Medical Science Liaison | Reveal Email/Phone |
AMAG Pharmaceuticals News
Co., Ltd., SGPharma Pvt. Ltd., Pfizer, Inc., AMAG Pharmaceuticals, Inc., Dr. Reddy's Laboratories, Octapharma AG, Bausch Health Companies Inc.,...
AMAG Pharmaceuticals Inc., Duchesnay Inc., Emotional Brain BV, Novo Nordisk AS, Sprout Pharmaceuticals Inc. The report provides a good overview...
... Teva Pharmaceutical Industries Ltd., AMAG Pharmaceuticals, Rockwell Medical, Akebia Therapeutics, Vifor Pharma Management Ltd.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $92.5M | 411 | -11% | N/A |
#2 | $75.8M | 418 | N/A | N/A |
#3 | $64.8M | 418 | 2% | N/A |
#4 | $128.5M | 423 | 3% | N/A |
#5 | $63.6M | 424 | -6% | N/A |
AMAG Pharmaceuticals Executives
Name | Title |
---|---|
Edward Myles | SVP/CFO/Treasurer |
Scott Myers | President and Chief Executive Officer |
Shannon Gath | Chief Information Officer |
Heather Haley | Executive Assistant to Chief Commercial Officer |
Edward Myles | SVP/CFO/Treasurer |
Scott Myers | President and Chief Executive Officer |
Michael Cressman | Vice President, Clinical Research |
Daniel Jorgensen | Vice President |
Carolyn Rucci | VP, Deputy General Counsel, Corporate |
Angel Stephens | Vice President, Consumer Sales and Service |
Judith Johnson | Vice President of Pharmacovigilance and Pharmacoepidemiology |
Mary Jo Mullen | Vice President, Managed Care |
Brian Robinson | Senior Vice President, Medical Affairs |
Rushmie N. | Vice President, Corporate Affairs and Investor Relations |
Judith Johnson | VP Pharmacovigilance and Pharmacoepidemiology |
Rachel Morten | VP, Regulatory & Nonclinical |
Carolyn Rucci | VP, Deputy General Counsel, Corporate |